Liquid biopsy: ready to guide therapy in advanced prostate cancer?

BJU International

Volumn 118, Issue 6, 2016, Pages 855-863

  Hegemann, Miriam ^a   Stenzl, Arnulf ^a   Bedke, Jens ^a   Chi, Kim N ^b,c   Black, Peter C ^b   Todenhöfer, Tilman ^a,b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b VANCOUVER PROSTATE CENTRE   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

biomarker; cell free DNA; circulating tumour cell; liquid biopsy; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; BIOLOGICAL MARKER; CD45 ANTIGEN; CELL FREE DNA; CIRCULATING RNA; CYTOKERATIN; DNA; EPITHELIAL CELL ADHESION MOLECULE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RNA; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; TUMOR MARKER;

ADVANCED CANCER; ANTIGEN BINDING; APOPTOSIS; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CELL COUNT; CELL EXPANSION; CELL VIABILITY; CIRCULATING TUMOR CELL; EPITHELIAL MESENCHYMAL TRANSITION; ERG GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; LIQUID PROSTATE BIOPSY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROTEIN EXPRESSION; REVIEW; BIOPSY; BLOOD; CANCER STAGING; MALE; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; BIOPSY; DNA, NEOPLASM; HUMANS; MALE; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS; RNA, NEOPLASM;

EID: 84995394883     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13586     Document Type: Review

References (67)

1. Gillessen S, Omlin A, Attard G et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2015; 26: 1589–604
2. Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373: 737–46
3. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411–22
4. Alix-Panabières C, Vendrell J-P, Pellé O et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007; 53: 537–9
5. Stott SL, Lee RJ, Nagrath S et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010; 2: 25ra23
6. Meyer CP, Pantel K, Tennstedt P et al. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. Urol Oncol 2016; 34: 235.e11–6
7. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302–9
8. ® system for detection of circulating tumor cells in prostate cancer patients. Anticancer Res 2012; 32: 3507–13
9. Park ES, Jin C, Guo Q et al. Continuous flow deformability-based separation of circulating tumor cells using microfluidic ratchets. Small 2016; 12: 1909–19
10. Ellis WJ, Pfitzenmaier J, Colli J, Arfman E, Lange PH, Vessella RL. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 2003; 61: 277–81
11. Stott SL, Hsu C-H, Tsukrov DI et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA 2010; 107: 18392–7
12. Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the cellsearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010; 2009: e617421
13. Attard G, de Bono JS. Utilizing circulating tumor cells: challenges and pitfalls. Curr Opin Genet Dev 2011; 21: 50–8
14. Crespo M, van Dalum G, Ferraldeschi R et al. Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. Br J Cancer 2015; 112: 1166–74
15. Beltran H, Jendrisak A, Landers M et al. The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer. Clin Cancer Res 2016; 22: 1510–9
16. Armstrong AJ, Marengo MS, Oltean S et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 2011; 9: 997–1007
17. Qin X, Park S, Duffy SP et al. Size and deformability based separation of circulating tumor cells from castrate resistant prostate cancer patients using resettable cell traps. Lab Chip 2015; 15: 2278–86
18. De Giorgi V, Pinzani P, Salvianti F et al. Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J Invest Dermatol 2010; 130: 2440–7
19. Werner SL, Graf RP, Landers M et al. Analytical validation and capabilities of the epic CTC platform: enrichment-free circulating tumour cell detection and characterization. J Circ Biomark 2015; 4: 3. doi: 10.5772/60725
20. Danila DC, Heller G, Gignac GA et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13: 7053–8
21. Scher HI, Jia X, de Bono JS et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009; 10: 233–9
22. Olmos D, Arkenau H-T, Ang JE et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009; 20: 27–33
23. Goldkorn A, Ely B, Quinn DI et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 2014; 32: 1136–42
24. Danila DC, Anand A, Sung CC et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 2011; 60: 897–904
25. Attard G, Swennenhuis JF, Olmos D et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009; 69: 2912–8
26. Gao D, Vela I, Sboner A et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 2014; 159: 176–87
27. Chen CL, Mahalingam D, Osmulski P et al. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate 2013; 73: 813–26
28. Sarioglu AF, Aceto N, Kojic N et al. A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Meth 2015; 12: 685–91
29. Aceto N, Bardia A, Miyamoto DT et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014; 158: 1110–22
30. Aceto N, Toner M, Maheswaran S, Haber DA. En route to metastasis: circulating tumor cell clusters and epithelial-to-mesenchymal transition. Trends Cancer 2015; 1: 44–52
31. Larson CJ, Moreno JG, Pienta KJ et al. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 2004; 62: 46–53
32. Miyamoto DT, Lee RJ, Stott SL et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2012; 2: 995–1003
33. Antonarakis ES, Lu C, Wang H et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371: 1028–38
34. Miyamoto DT, Zheng Y, Wittner BS et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science 2015; 349: 1351–6
35. Steinestel J, Luedeke M, Arndt A et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 2015; [Epub ahead of print]. doi: 10.18632/oncotarget.3925
36. Todenhöfer T, Azad A, Stewart C et al. Correlation of a novel whole blood RT-PCR assay measuring AR-V7 expression with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI). J Urol 2016; 34 (Suppl. 2S): [Epub ahead of print]. doi: 10.1016/j.juro.2016.06.094. abstr 223
37. Antonarakis ES, Lu C, Luber B et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 2015; 1: 582–91
38. Onstenk W, Sieuwerts AM, Kraan J et al. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol 2015; 68: 939–45
39. Scher HI, Lu D, Schreiber NA et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2016; [Epub ahead of print]. doi: 10.1001/jamaoncol.2016.1828
40. Barbieri CE, Bangma CH, Bjartell A et al. The mutational landscape of prostate cancer. Eur Urol 2013; 64: 567–76
41. Scheble VJ, Braun M, Beroukhim R et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010; 23: 1061–7
42. Reig Ò, Marín-Aguilera M, Carrera G et al. TMPRSS2-ERG in blood and docetaxel resistance in metastatic castration-resistant prostate cancer. Eur Urol 2016; [Epub ahead of print]. doi: 10.1016/j.eururo.2016.02.034
43. Punnoose EA, Ferraldeschi R, Szafer-Glusman E et al. PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. Br J Cancer 2015; 113: 1225–33
44. Haffner MC, Mosbruger T, Esopi DM et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest 2013; 123: 4918–22
45. Beltran H, Tomlins S, Aparicio A et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 2014; 20: 2846–50
46. Chen JF, Ho H, Lichterman J et al. Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. Cancer 2015; 121: 3240–51
47. Ferraldeschi R, McDaniel A, Krupa R et al. CK- and small nuclear size circulating tumor cell (CTCs) phenotypes in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2014; 32 (Suppl. 4): abstr 209
48. Scher HI, Heller G, Molina A et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol 2015; 33: 1348–55
49. Azad AA, Volik SV, Wyatt AW et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res 2015; 21: 2315–24
50. Romanel A, Gasi Tandefelt D, Conteduca V et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med 2015; 7: 312re10
51. Wyatt AW, Azad AA, Volik SV et al. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol 2016; [Epub ahead of print]. doi: 10.1001/jamaoncol.2016.0494
52. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA: Apoptosis and active DNA release. Clin Chim Acta 2001; 313: 139–42
53. Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426–37
54. Liang DH, Ensor JE, Liu Z-B et al. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients. Breast Cancer Res Treat 2016; 155: 139–49
55. Janku F, Angenendt P, Tsimberidou AM et al. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 2015; 6: 12809–21
56. Boddy JL, Gal S, Malone PR, Harris AL, Wainscoat JS. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res 2005; 11: 1394–9
57. Kienel A, Porres D, Heidenreich A, Pfister D. cfDNA as a prognostic marker of response to taxane based chemotherapy in patients with prostate cancer. J Urol 2015; 194: 966–71
58. Jung K, Stephan C, Lewandowski M et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett 2004; 205: 173–80
59. Frenel JS, Carreira S, Goodall J et al. Serial next generation sequencing of circulating cell-free DNA evaluating tumour clone response to molecularly targeted drug administration. Clin Cancer Res 2015; 21: 4586–96
60. Chedgy EC, Annala M, Beja K et al. Moving toward personalized care: liquid biopsy predicts response to cisplatin in an unusual case of BRCA2-Null neuroendocrine prostate cancer. Clin Genitourin Cancer 2016; 14: e233–6
61. Mateo J, Carreira S, Sandhu S et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015; 373: 1697–708
62. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513–8
63. Agaoglu F, Kovancilar M, Dizdar Y et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biol 2011; 32: 583–8
64. Shen J, Hruby GW, McKiernan JM et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 2012; 72: 1469–77
65. Zhang HL, Yang LF, Zhu Y et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011; 71: 326–31
66. Lin HM1, Castillo L, Mahon KL et al. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer 2014; 110: 2462–71
67. Olmos D, Brewer D, Clark J et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol 2012; 13: 1114–24